# OnCo record tarlatamab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/tarlatamab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "tarlatamab" ;
  schema:name "Tarlatamab"@en ;
  schema:description "The first T-cell engager to improve survival in a common solid tumour, small-cell lung cancer."@en ;
  schema:url <https://onco.cc/drugs/tarlatamab/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Tarlatamab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q124312898> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Tarlatamab>, <https://www.nice.org.uk/guidance/ta1091> ;
  onco:status "approved" ;
  onco:modality "Bispecific T-cell engager (DLL3×CD3)" ;
  schema:alternateName "Imdelltra" ;
  onco:approval "US 2024: Extensive-stage SCLC after platinum chemotherapy", "EU 2026: ES-SCLC after platinum-based chemotherapy; 29 May 2026", "England (NICE) 2025: Extensive-stage small-cell lung cancer progressing after two or more lines of treatment including platinum-based chemotherapy: not recommended" ;
  onco:acceleratedApproval "US 2024-05-16: Adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy" ;
  onco:acceleratedApprovalConfirmed "US 2025-11-19: Adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy" ;
  onco:cancers <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/extensive-stage-sclc/>, <https://onco.cc/cancers/limited-stage-sclc/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/> ;
  onco:targets <https://onco.cc/targets/dll3/>, <https://onco.cc/targets/cd3/> ;
  onco:companies <https://onco.cc/companies/amgen/> ;
  onco:terms <https://onco.cc/terms/crs/> ;
  onco:trials <https://onco.cc/trials/dellphi-304/>, <https://onco.cc/trials/nct07005128/>, <https://onco.cc/trials/nct06117774/>, <https://onco.cc/trials/nct07778316/>, <https://onco.cc/trials/nct06502977/>, <https://onco.cc/trials/nct05060016/>, <https://onco.cc/trials/nct06745323/>, <https://onco.cc/trials/dellphi-305/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-dellphi-301-nejm-2023/> .